Z-350, a novel compound with alpha 1-adrenoceptor antagonistic and steroid 5 alpha-reductase inhibitory actions: pharmacological properties in vivo.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS(1999)
Abstract
The alpha(1)-adrenoceptor-antagonistic and steroid 5 alpha-reductase-inhibitory actions of Z-350 ([S)-4-{3-{4-{1 -(4-methylphenyl)-3-[4(2-methoxyphenyl)piperazine-1 -yl]propoxy}benzoyl}indole-1-yl}butyric acid hydrochloride] were investigated in rabbits and rats in vivo. Z-350 (1-30 mg/kg), administered intraduodenally, dose-dependently inhibited phenylephrine-induced increases in prostatic urethral pressure with an ED,, value of 3.8 mg/kg in anesthetized male rabbits, whereas the effects on mean blood pressure and orthostatic hypotensive response were weaker when compared with other alpha(1)-adrenoceptor antagonists, tamsulosin and prazosin. Z-350 (1-10 mg/kg p.o.) dose-dependantly inhibited the prostatic steroid 5 alpha-reductase activity in rats with an ED50 value of 2.8 mg/kg. The daily oral administration of Z-350, at greater than or equal to 10 mg/kg for 7 days, significantly reduced the prostatic growth induced by testosterone in castrated rats, with no effect on dihydrotestoterone-induced prostatic growth. These results indicate that Z-350 exhibited alpha(1)-adrenoceptor-antagonistic and 5 alpha-reductase inhibitory actions at almost equal doses in vivo, and was expected to improve the bladder outlet obstruction associated with benign prostatic hyperplasia with smaller cardiovascular adverse effect.
MoreTranslated text
Key words
steroid,novel compound,pharmacological properties,alpha-reductase
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined